RolandBWalterMDPhD MS

Hematology • Seattle, WA

Hematologic Oncology

Professor, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center

Join to view full profile

Dr. Walter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walter's full profile

Already have an account?

Office
1100 Fairview Ave N, D1-100
Seattle, WA 98109

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
University of Zurich Faculty of MedicineClass of 1996

Certifications & Licensure

WA State Medical License 2006 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2008 Dec 01
Completed
Not Applicable
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Start of enrollment: 2009 May 01
Completed
Phase 1, Phase 2
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia Start of enrollment: 2010 Oct 01
Completed
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 2
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2011 Apr 01
Terminated
Phase 1, Phase 2
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission Start of enrollment: 2012 Jul 01
Completed
Phase 1
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Start of enrollment: 2012 Dec 20
Completed
Phase 1, Phase 2
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2013 May 07
Completed
Not Applicable
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Start of enrollment: 2014 Jan 23
Completed
Phase 1, Phase 2
Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy Start of enrollment: 2015 Jan 09
Terminated
Not Applicable
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Start of enrollment: 2016 Dec 30
Completed
Phase 2
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm Start of enrollment: 2018 Sep 14
Completed
Phase 1, Phase 2
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Start of enrollment: 2020 Mar 11
Recruiting
Phase 2
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS Start of enrollment: 2021 Dec 16
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Geoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, Robert K Stuart, Roland B Walter
Blood Advances. 2024-12-24
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.
Khushboo V Pal, Megan Othus, Zahra Ali, Katherine Russell, Carole Shaw
Blood Advances. 2024-12-24
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.
Corentin Orvain, Filippo Milano, Eduardo Rodríguez-Arbolí, Megan Othus, Effie W Petersdorf
Leukemia. 2024-12-12

Journal Articles

Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...
Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials
Brent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature
Relationship Between CD33 Expression, Splicing Polymorphism, and in Vitro Cytotoxicity of Gemtuzumab Ozogamicin and the CD33/CD3 BiTErAMG 330
Colin D Godwin, Roland B Walter, Haematologica
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
Join now to see all

Abstracts/Posters

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myel...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
Roland B. Walter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
COVA4231, a Potent CD3/CD33 Bispecific FynomAb with IgG-like Pharmacokinetics for the Treatment of Acute Myeloid Leukemia
Roland Walter, MD, Nature, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Novel Therapies for AML: Expanding Future Options
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

MRD and Relapse in Patients with AMLAugust 17th, 2022
NCI Partners with Cancer Research UK, JADPRO Appoints Beth Faiman as Editor-in-Chief, and MoreOctober 1st, 2020
Shop TalkSeptember 5th, 2020
Join now to see all

Grant Support

Prognostic And Functional Significance Of Adhesion Molecules In Pediatric AMLNational Cancer Institute2012
Impact Of Genetic Variation On Response To GO Therapy In Cog-Aml Clinical TrialsNational Cancer Institute2012
AML Stem Cell Heterogeneity: Implications For Gemtuzumab Ozogomicin-Based TherapyNational Cancer Institute2009